Logo Image
|Videos|September 11, 2020

Testing Reagents for SARS CoV 2: Institutional Stockpiling and Supply Chain Issues

Robert H. Christenson, PhD, University of Maryland, outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.

Does the testing reagent stockpile for COVID-19 impact other conditions? According to Robert H. Christenson, PhD, a professor at University of Maryland Medical School, not directly.

Many of the necessary components for mass testing are SARS-CoV-2 specific. This has led to a stockpiling of resources by various institutions, but has not impinged on the supply of reagents broadly.

In this segment, Dr. Christenson outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.

According to the US Centers for Disease Control and Prevention (CDC) the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel contains 4 reagents:

There are 3 primer-probe mixes for:

  • 2019-nCoV_N1: targets virus nucleocapsid (N) gene for specific detection of SARS-CoV-2
  • 2019-nCoV_N2: targets virus nucleocapsid (N) gene for specific detection of SARS-CoV-2
  • RP: targets human RNase P gene for detection of human nucleic acids; control for sample integrity

As well as a 4th noninfectious positive control material which yields a positive result in each assay included in the panel.

Related to this article

View more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more
Measles Update: October 23, 2026
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Measles Update: October 16, 2026
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
Read more